Tissue penetration and activity of camptothecins in solid tumor xenografts

Molecular Cancer Therapeutics

Volumn 13, Issue 11, 2014, Pages 2727-2737

  Kyle, Alastair H ^a   Baker, Jennifer H E ^b   Gandolfo, Maria Jose ^a   Reinsberg, Stefan A ^b   Minchinton, Andrew I ^a  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; CAMPTOTHECIN; FIRTECAN; IRINOPHORE C; IRINOTECAN; PIMONIDAZOLE; TOPOTECAN; UNCLASSIFIED DRUG; DNA TOPOISOMERASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOFLUORESCENCE; CELL PROLIFERATION; COLORECTAL TUMOR; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG FORMULATION; DRUG PENETRATION; DRUG SCREENING; DRUG STABILITY; DRUG TARGETING; EXTRAVASCULAR SPACE; FEMALE; FROZEN SECTION; HCT116 CELL LINE; HT 29 CELL LINE; MOUSE; NONHUMAN; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; VASCULAR TUMOR; ANALOGS AND DERIVATIVES; ANIMAL; COLONIC NEOPLASMS; DRUG EFFECTS; HUMAN; METABOLISM; NONOBESE DIABETIC MOUSE;

ANIMALS; CAMPTOTHECIN; CELL PROLIFERATION; COLONIC NEOPLASMS; FEMALE; HCT116 CELLS; HT29 CELLS; HUMANS; MICE; MICE, INBRED NOD; TOPOISOMERASE I INHIBITORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84918802127     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0475     Document Type: Article

References (37)

1. Basili S, Moro S. Novel camptothecin derivatives as topoisomerase I inhibitors. Expert Opin Ther Patents 2009;19:555-74.
2. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, et al. Antitumor-activity of 7-Ethyl-10-[4-(1-Piperidino)-1-piperidino] carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987;47:5944-7.
3. Wall ME, Wani MC. Camptothecin and taxol: discovery to clinic- thirteenth bruce F. Cain memorial award lecture. Cancer Res 1995; 55:753-60.
4. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873-8.
5. Schluep T. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res 2006;12: 1606-14.
6. Ramsay EC, Anantha M, Zastre J, Meijs M, Zonderhuis J, Strutt D, et al. Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors. Clin Cancer Res 2008;14:1208-17.
7. Weiss GJ, Chao J, Neidhart JD, Ramanathan RK, Bassett D, Neidhart JA, et al. First-in-human phase 1/2a trial of CRLX101, a cyclodextrincontaining polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest New Drugs 2013; 31:986-1000.
8. Hamaguchi T, Doi T, Eguchi-Nakajima T, Kato K, Yamada Y, Shimada Y, et al. Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors. Clin Cancer Res 2010;16:5058-66.
9. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006;6:583-92.
10. Jain RJ. Barriers to drug delivery in solid tumours. Sci Amer 1994;7: 59-65.
11. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 1997;26:71-90.
12. Tannock IF, Lee CM, Tunggal JK, Cowan DS, Egorin MJ. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 2002;8:878-84.
13. André T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP, et al. CPT-11 (Irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. Eur J Cancer 1999;35: 1343-7.
14. Hoskins P, Eisenhauer E, Beare S, Roy M, Drouin P, Stuart G, et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a national cancer institute of Canada clinical trials group study. J Clin Oncol 1998; 16:2233-7.
15. Houghton PJ, Cheshire PJ, Hallman JC, Bissery MC, MATHIEUBOUE A, Houghton JA. Therapeutic efficacy of the topoisomerase-I inhibitor 7-Ethyl-10-(4-[1-Piperidino]-1-Piperidino)-carbonyloxy-camptothecin against human tumor xenografts - lack of cross-resistance invivo in tumors with acquired-resistance to the topoisomerase-I inhibitor 9- dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res 1993; 53:2823-9.
16. Houghton PJ, Cheshire PJ, Hallman JDII, Lutz L, Friedman HS, Danks MK, et al. Ef ficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995;36:393-403.
17. Zamboni WC, Stewart CF, Cheshire PJ, Richmond LB, Hanna SK, Luo XL, et al. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models. Clin Cancer Res 1998;4:743-53.
18. Guichard S, Montazeri A, Chatelut E, Hennebelle I, Bugat R, Canal P. Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: Pharmacokinetic and pharmacodynamic evaluation. Clin Cancer Res 2001;7:3222-8.
19. Hertzberg RP, Caranfa MJ, Holden KG, Jakas DR, Gallagher G, Mattern MR, et al. Modification of the hydroxy lactone ring of camptothecin -inhibition of mammalian topoisomerase-I and biologicalactivity. J Med Chem 1989;32:715-20.
20. Mathijssen R, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT- 11). Clin Cancer Res 2001;7:2182-94.
21. Burke TG, Mishra AK, Wani MC, Wall ME. Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry 1993;32:5352-64.
22. Xu C, Barchet TM, Mager DE. Quantitative structure-property relationships of camptothecins in humans. Cancer Chemother Pharmacol 2009;65:325-33.
23. Tentori L. Inhibition of poly(ADP-ribose) polymerase prevents irino-tecan- induced intestinal damage and enhances irinotecan/temozolomide ef ficacy against colon carcinoma. FASEB J 2006;20: 1709-11.
24. Bhonde MR, Hanski M-L, Budczies J, Cao M, Gillissen B, Moorthy D, et al. DNA damage-induced expression of p53 suppresses mitotic checkpoint kinase hMps1 - The lack of this suppression in p53(MUT) cells contributes to apoptosis. J Biol Chem 2006;281: 8675-85.
25. Bhonde MR, Hanski M-L, Notter M, Gillissen BF, Daniel PT, Zeitz M, et al. Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth. Oncogene 2006;25:165-75.
26. Magrini R, Bhonde MR, Hanski M-L, Notter M, Scherbl H, Boland CR, et al. Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int J Cancer 2002;101:23-31.
27. Abal M, Bras-Goncalves R, Judde J-G, Fsihi H, de Cremoux P, Louvard D, et al. Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line. Oncogene 2004; 23:1737-44.
28. Baker JHE, Kyle AH, Bartels KL, Methot SP, Flanagan EJ, Balbirnie A, et al. Targeting the tumour vasculature: exploitation of lowoxygenation and sensitivity toNOS inhibition by treatment with a hypoxic cytotoxin. PLoS ONE 2013;8:e76832.
29. Kyle AH, Huxham LA, Yeoman DM, Minchinton AI. Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors. Clin Cancer Res 2007;13:2804-10.
30. Huxham LA, Kyle AH, Baker JH, Nykilchuk LK, Minchinton AI. Microregional effects of gemcitabine in HCT-116 xenografts. Cancer Res 2004;64:6537-41.
31. Kyle AH, Huxham LA, Chiam AS, Sim DH, Minchinton AI. Direct assessment of drug penetration into tissue using a novel application of three-dimensional cell culture. Cancer Res 2004;64:6304-9.
32. Kyle AH, Baker JHE, Minchinton AI. Targeting quiescent tumor cells via oxygen and IGF-I supplementation. Cancer Res 2012;72:801-9.
33. Minchinton AI, Wendt KR, Clow KA, Fryer KH. Multilayers of cells growing on a permeable support: An in vitro tumour model. Acta Oncologica 1997;36:13-6.
34. Cowan DSM, Hicks KO, Wilson WR. Multicellular membranes as an in vitro model for extravascular diffusion in tumours. Br JCancer 1996;74: S28-31.
35. Phillips RM, Loadman PM, Cronin BP. Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. Br J Cancer 1998;77:2112-9.
36. Loos WJ, de Bruijn P, Verweij J, Sparreboom A. Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography. Anti-Cancer Drugs 2000;11: 315-24.
37. Tang X, Falls DL, Li X, Lane T, Luskin MB. Antigen-retrieval procedure for bromodeoxyuridine immunolabeling with concurrent labeling of nuclear DNA and antigens damaged by HCl pretreatment. J Neurosci 2007;27:5837-44.